TRIP6 is an adaptor protein that regulates cell motility and antiapoptotic signaling. Although it has been implicated in tumorigenesis, the underlying mechanism remains largely unknown. Here we provide evidence that TRIP6 promotes tumorigenesis by serving as a bridge to promote the recruitment of p27 KIP1 to AKT in the cytosol. TRIP6 regulates the membrane translocation and activation of AKT and facilitates AKT-mediated recognition and phosphorylation of p27 KIP1 specifically at T157, thereby promoting the cytosolic mislocalization of p27 KIP1 . This is required for p27 KIP1 to enhance lysophosphatidic acid (LPA)-induced ovarian cancer cell migration. TRIP6 also promotes serum-induced reduction of nuclear p27 KIP1 expression levels through Skp2-dependent and -independent mechanisms. Consequently, knockdown of TRIP6 in glioblastoma or ovarian cancer xenografts restores nuclear p27 KIP1 expression and impairs tumor proliferation. As TRIP6 is upregulated in gliomas and its levels correlate with poor clinical outcomes in a dose-dependent manner, it may represent a novel prognostic marker and therapeutic target in gliomas.T hyroid hormone receptor-interacting protein 6 (TRIP6) is a zyxin-related adaptor protein and focal adhesion molecule (1). Through its three LIM domains, PDZ-binding motif, Crk SH2-binding motif, and several putative SH3-binding domains, TRIP6 associates with a variety of molecules from the cell surface to the nucleus to regulate actin reorganization, focal adhesion assembly/disassembly, cell migration/invasion, antiapoptotic signaling, and transcriptional control. Notably, TRIP6 binds to lysophophatidic acid (LPA) receptor 2 (LPA 2 ) and the Fas/CD95 receptor to promote LPA-and Fas ligand-induced cell migration in a c-Src-dependent manner (2-4). TRIP6 can also regulate prosurvival signaling via activation of NF-B, extracellular signal-regulated kinase (ERK), and phosphatidylinositol 3-kinase (PI3K)/ AKT (3, 5), and nuclear TRIP6 acts as a transcriptional coregulator of AP-1 and NF-B (6). These data suggest that TRIP6 functions at a point of convergence of multiple signaling pathways critical for cancer development.We recently showed that TRIP6 is overexpressed in glioblastomas (3). By analyzing the survival of glioma patients, we found that the increased expression level of TRIP6 correlates significantly with poor clinical outcomes. Although these findings implicate a role for TRIP6 in cancer progression, the precise function of TRIP6 in tumorigenesis remains largely unknown. To address this issue, we examined the effect of TRIP6 knockdown on the proliferation of glioblastoma and ovarian cancer cell lines that express TRIP6 at high levels. These studies reveal a novel role for TRIP6 in tumorigenesis by promoting the loss of nuclear p27 KIP1